Navigation Links
Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
Date:10/10/2007

SAN CARLOS, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that preclinical data for its proprietary product candidate NKTR-102 (PEG-irinotecan) will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Therapeutics in San Francisco, California on October 25, 2007. The presentations will highlight new results from preclinical trials of NKTR-102 in mouse models of colorectal, lung and breast cancers. NKTR-102 is a PEGylated form of irinotecan created using Nektar's innovative small molecule PEGylation technology platform and is in Phase 1 clinical development for the treatment of solid tumors.

In preclinical studies presented at ECCO 14 in September, NKTR-102 substantially suppressed tumor growth in an irinotecan-resistant mouse colorectal tumor model, while irinotecan-treated groups did not show a statistically significant decrease in tumor growth compared to controls. Further, administration of NKTR-102 resulted in a significantly improved pharmacokinetic profile for the active metabolite of irinotecan as compared to treatment with irinotecan.

"The studies for NKTR-102 continue to indicate that Nektar's small molecule PEGylation technology can be a powerful platform for improving chemotherapeutic agents," Tim Riley, Ph.D., Vice President of PEGylation Research at Nektar. "The new preclinical data in colorectal, lung and breast tumor models also highlights the promise of NKTR-102 to serve as a potentially new and powerful therapy in multiple solid tumor settings."

Two poster presentations are scheduled:

October 25, 2007 - 12:30 PM - 2:00 PM (PT); 5:30 - 7:30 PM (PT)

Poster Session C -- AACR-NCI-EORTC
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
2. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
3. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
4. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
5. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
6. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
7. Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... to present a corporate overview and update at the Piper ... 2, 2014, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific ... New York . A live audio webcast ... section of Arena,s website at www.arenapharm.com . A replay ...
(Date:11/24/2014)... , Nov. 24, 2014  Marta Rendon, MD, founder of ... Boca Raton , FL and international key opinion leader in ... the United States to attend the ... Istanbul, Turkey . Here, at this gathering of over ... world renowned facial plastic surgery experts from Asia ...
(Date:11/24/2014)... CLEVELAND , Nov. 24, 2014  Surgical Theater, ... at the November 24 th opening of ... IRCCS Istituto Neurologico Nazionale "C. Besta." The SuRgical Planner ... be showcased at the event for their 3D navigation ... Dr. Joshua Bederson , Professor and Chair, Department ...
Breaking Medicine Technology:Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 3Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 2Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 3Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 3
... ,Oct. 19, 2011 Innocoll, Inc. announced it has ... Pharma in China for CollaGUARD surgical adhesion barrier for ... surgery.   Dr. Michael Myers, President and ... China is becoming an increasingly important and dynamic market ...
... YORK, Oct. 19, 2011 Reportlinker.com announces that ... its catalogue: Syncria (Type ... http://www.reportlinker.com/p0657174/Syncria-Type-2-Diabetes-–-Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... Forecasts to 2020 Summary ...
Cached Medicine Technology:Innocoll Enters Partnership With Pioneer Pharma in China for the Distribution of CollaGUARD 2Innocoll Enters Partnership With Pioneer Pharma in China for the Distribution of CollaGUARD 3Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 2Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 3Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 4Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 5
(Date:11/26/2014)... 26, 2014 The family foundation of ... the Mesothelioma Applied Research Foundation (Meso Foundation), half of ... Patient Travel Grant Program . The focus area ... create grant partnerships with organizations that can generate transformational ... Schulze is the founder and chairman emeritus of Best ...
(Date:11/26/2014)... 26, 2014 German scientists say carbon-based ... can cause mesothelioma that looks and acts similar to ... article on the research. Click here to read ... for Toxicology and Experimental Medicine in Hannover injected 500 ... of the rats eventually developed mesothelioma , how ...
(Date:11/26/2014)... 26, 2014 With a redesign of ... Steven Meier has enhanced the user experience and ... prospective patients an online destination for orthopedic and sports ... present the new and improved version of the website. ... easier than ever for current and prospective patients to ...
(Date:11/26/2014)... 2014 ISI Telemanagement Solutions, Inc., ... been award the 2014 Lync Pioneer Award ... comes as a great honor to ISI, who ... ecosystem. Specifically, ISI offers an integrated collaboration reporting ... communication, including voice, video, Lync IM, and conferencing. ...
(Date:11/26/2014)... For those with a New Year’s resolution to get ... at the University of Colorado Anschutz Health and Wellness ... The 45- 60 minute classes have just started and are ... club memberships. , LES MILLS BODYPUMP™ exercise classes strengthen, condition ... at fast results , By focusing on low weight ...
Breaking Medicine News(10 mins):Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 2Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 3Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:Los Angeles Orthopedic Surgeon Dr. Steven Meier Announces Relaunch Of Practice Website 2Health News:ISI Telemanagement Solutions, Inc. has been Awarded the 2014 Microsoft Lync Pioneer Award 2Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2
... ATLANTA, Sept. 8 Craneware, Inc. (AIM: CRW.L), a leader in sustainable financial improvement ... ended June 30, 2009. , , Financial Highlights , ... in the year totaling $43.2m (FY08: $25.7m), 68% up from the previous year, contributing ... to $23.0m (FY08: $18.7m) , 51% ...
... , , WASHINGTON, Sept. 8 More ... in scrubs and lab coats this week to bring an angry message ... The doctors, all traveling as individuals and at their own expense, will ... meet with the doctors of Congress, including Tom Price, M.D. (GA) and ...
... , , , ... and Walmart,s Leslie Dach to discuss areas of bipartisan agreement in ... The Bipartisan Policy Center (BPC) and Better Health Care Together ... agreement among political, business and labor leaders in the health reform ...
... maintained in mice given HDAC inhibitors, study finds , TUESDAY, ... cancer drug might be able to restore day-to-day memory ... common form of dementia among the elderly, is expected to ... sign is loss of short-term memory. , "People often joke ...
... , BRISTOL, Va. and BIRMINGHAM, Ala., ... (NYSE: HLS ) today announced that a joint venture ... of public need (COPN) to open a new inpatient rehabilitation hospital ... Bristol and throughout Southwest Virginia to have access to comprehensive, high-quality ...
... , NEW YORK, Sept. 8 ... its catalogue. , , Lung Cancer ... http://www.reportlinker.com/p0131247/Lung-Cancer-Therapeutics.html , , This report ... Millions of US$. The US market for Non-Small Cell Lung Cancer ...
Cached Medicine News:Health News:Craneware Announces Fiscal Year-End Results 2Health News:Craneware Announces Fiscal Year-End Results 3Health News:Dr. 'Smith' Comes to Washington: Angry Physicians From All 50 States Rally in DC on Sept 10 2Health News:Bipartisan Policy Center and Better Health Care Together to Host Joint Health Care Forum Tomorrow 2Health News:Wellmont, HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 2Health News:Wellmont, HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 3Health News:Wellmont, HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 4Health News:Wellmont, HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 5Health News:Reportlinker Adds Lung Cancer Therapeutics Report 2Health News:Reportlinker Adds Lung Cancer Therapeutics Report 3Health News:Reportlinker Adds Lung Cancer Therapeutics Report 4Health News:Reportlinker Adds Lung Cancer Therapeutics Report 5Health News:Reportlinker Adds Lung Cancer Therapeutics Report 6Health News:Reportlinker Adds Lung Cancer Therapeutics Report 7Health News:Reportlinker Adds Lung Cancer Therapeutics Report 8Health News:Reportlinker Adds Lung Cancer Therapeutics Report 9Health News:Reportlinker Adds Lung Cancer Therapeutics Report 10